Alexander Gerard R, Biccard Bruce
King Dinuzulu Hospital, Durban, South Africa
King Dinuzulu Hospital, Durban, South Africa Department of Anaesthesiology, Inkosi Albert Luthuli Central Hospital, Durban, South Africa.
Eur J Cardiothorac Surg. 2016 Mar;49(3):823-8. doi: 10.1093/ejcts/ezv228. Epub 2015 Jul 4.
This review was undertaken to compare treatment outcomes in human immunodeficiency virus (HIV) negative versus HIV-positive patients following adjuvant lung resection for drug-resistant tuberculosis (DR-TB) in patients deemed feasible for surgery. Despite appropriate medical therapy, mortality remains extremely high and cure rates poor in patients with DR-TB and HIV co-infection. Therefore, adjuvant lung resection may warrant a more prominent role in the treatment of these patients.
A retrospective review of all case records from 1 January 2012 to 31 March 2013 of all patients admitted to the Department of Cardiothoracic Surgery King Dinuzulu Hospital with DR-TB and treated with adjuvant lung resection was undertaken. Prior to surgery, all patients were treated for at least 3 months with appropriate drug therapy for DR-TB. This was continued for the recommended period following lung resection.
Fourteen patients with extensively drug-resistant tuberculosis (XDR-TB) were deemed suitable for lung resection. Of these patients, 10 patients were HIV-positive and 4 were HIV-negative. In the XDR-TB/HIV-positive group, 7 patients were cured, 2 converted and 2 patients developed a post-pneumonectomy broncho-pleural fistula. One patient was lost to follow-up. In the XDR-TB/HIV-negative group, 1 patient was cured, 3 converted and 1 patient developed a post-thoracotomy superficial wound infection. There was no in-hospital mortality in both groups. Thirty-six patients with multi-drug-resistant tuberculosis (MDR-TB) were deemed suitable for lung resection. Of these patients, 19 were HIV-positive and 17 HIV-negative. In the MDR-TB/HIV-positive group, 12 patients were cured and 6 converted. One patient developed a post-thoracotomy superficial wound infection and another patient who developed a post-pneumonectomy empyema thoracis was also regarded as a treatment failure. In the MDR-TB/HIV-negative group, 15 patients were cured, 2 converted and 1 patient developed a post-pneumonectomy lower respiratory tract infection which necessitated a short period of mechanical ventilation. There was no in-hospital mortality in both groups.
Lung resection for DR-TB may be safely undertaken in selected patients who are HIV-positive with cure rates equivalent to that of HIV-negative patients. More importantly, these patients also have significantly higher cure rates than those patients treated with medical therapy alone.
本综述旨在比较在被认为适合手术的患者中,接受耐多药结核病(DR-TB)辅助性肺切除术后,人类免疫缺陷病毒(HIV)阴性与HIV阳性患者的治疗结果。尽管进行了适当的药物治疗,但DR-TB与HIV合并感染患者的死亡率仍然极高,治愈率很低。因此,辅助性肺切除在这些患者的治疗中可能值得发挥更突出的作用。
对2012年1月1日至2013年3月31日在迪努祖鲁国王医院心胸外科住院并接受DR-TB辅助性肺切除治疗的所有患者的病历进行回顾性研究。术前,所有患者均接受了至少3个月的DR-TB适当药物治疗。肺切除术后按推荐疗程继续治疗。
14例广泛耐药结核病(XDR-TB)患者被认为适合肺切除。其中,10例患者为HIV阳性,4例为HIV阴性。在XDR-TB/HIV阳性组中,7例患者治愈,2例转阴,2例发生肺切除术后支气管胸膜瘘。1例患者失访。在XDR-TB/HIV阴性组中,1例患者治愈,3例转阴,1例发生开胸术后浅表伤口感染。两组均无院内死亡。36例耐多药结核病(MDR-TB)患者被认为适合肺切除。其中,19例为HIV阳性,17例为HIV阴性。在MDR-TB/HIV阳性组中,12例患者治愈,6例转阴。1例发生开胸术后浅表伤口感染,另1例发生肺切除术后脓胸的患者也被视为治疗失败。在MDR-TB/HIV阴性组中,15例患者治愈,2例转阴,1例发生肺切除术后下呼吸道感染,需要短期机械通气。两组均无院内死亡。
对于选定的HIV阳性患者,DR-TB的肺切除可以安全进行,治愈率与HIV阴性患者相当。更重要的是,这些患者的治愈率也明显高于单纯接受药物治疗的患者。